Glaukos Corporation (GKOS)

NYSE: GKOS · IEX Real-Time Price · USD
109.79
-0.62 (-0.56%)
May 17, 2024, 4:00 PM EDT - Market closed
-0.56%
Market Cap 5.54B
Revenue (ttm) 326.43M
Net Income (ttm) -140.87M
Shares Out 50.37M
EPS (ttm) -2.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 347,032
Open 110.84
Previous Close 110.41
Day's Range 107.46 - 110.99
52-Week Range 54.38 - 113.97
Beta 1.08
Analysts Strong Buy
Price Target 105.50 (-3.91%)
Earnings Date May 1, 2024

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR,... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 25, 2015
Employees 907
Stock Exchange NYSE
Ticker Symbol GKOS
Full Company Profile

Financial Performance

In 2023, Glaukos's revenue was $314.71 million, an increase of 11.26% compared to the previous year's $282.86 million. Losses were -$134.66 million, 35.8% more than in 2022.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price forecast is $105.5, which is a decrease of -3.91% from the latest price.

Price Target
$105.5
(-3.91% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Glaukos Announces First Quarter 2024 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

17 days ago - Business Wire

Glaukos Announces the Release of its 2023 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

4 weeks ago - Business Wire

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

5 weeks ago - Business Wire

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

6 weeks ago - Business Wire

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

6 weeks ago - Business Wire

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

3 months ago - Business Wire

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

3 months ago - Business Wire

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

4 months ago - Business Wire

Alger's Amy Zhang gives her top small-cap stock picks for 2024

Amy Zhang, Amy Zhang Executive Vice President & Portfolio Manager at Alger, discusses the small-cap stocks she believes will outperform this year.

Other symbols: NTRA
4 months ago - CNBC Television

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

5 months ago - Business Wire

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

5 months ago - Business Wire

Glaukos Announces Participation in Stifel Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

6 months ago - Business Wire

Glaukos Announces Third Quarter 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

7 months ago - Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

7 months ago - Business Wire

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

7 months ago - Business Wire

Glaukos Announces Participation in Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

9 months ago - Business Wire

Glaukos Announces Second Quarter 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

10 months ago - Business Wire

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

10 months ago - Business Wire

Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

11 months ago - Business Wire

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire

Glaukos Announces Participation in the William Blair Growth Stock Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire

Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire

Glaukos Announces First Quarter 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire

Glaukos Announces the Release of its 2022 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

1 year ago - Business Wire